Cart
sales@molnova.com
Abrezekimab
CAS No. 2043952-59-4
Abrezekimab( —— )
Catalog No. M36767 CAS No. 2043952-59-4
Abrezekimab (VR 942) is composed of CDP7766, leucine, and trehalose. Abrezekimab is a humanized antibody that targets human IL-13.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 439 | Get Quote |
|
| 5MG | 717 | Get Quote |
|
| 10MG | 1121 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAbrezekimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionAbrezekimab (VR 942) is composed of CDP7766, leucine, and trehalose. Abrezekimab is a humanized antibody that targets human IL-13.
-
DescriptionAbrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetIL Receptor
-
RecptorIL Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2043952-59-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Burgess G, et, al. Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942. EBioMedicine. 2018 Sep;35:67-75.?
molnova catalog
related products
-
Vunakizumab
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis .
-
Platycodin D2
Platycodin D2 , a less hemolytic saponin, can improve specific cellular and humoral responses to hepatitis B surface antigen in mice, it could be safely used as adjuvant eliciting Th1 and Th2 immune responses.
-
Canakinumab
Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively.
